Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Rakovina Therapeutics Announces Q2 2026 Financial Results and Provides Corporate Update

All dollar amounts reflected in Canadian dollars unless otherwise stated. VANCOUVER, British Columbia, Aug. 31, 2026 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV) (FSE: 7JO0), a biopharmaceutical company advancing innovative cancer therapies through AI-powered drug discovery, today announced its financial results for the three and six months ended June 30, 2026 (“Q2 2026” and “YTD 2026”, respectively), and provided an update on recent corporate developments.

Rakovina Therapeutics Announces Final Closing of Upsized Non-Brokered Private Placement

Financing completed at the full upsized amount following strong investor demand Financing completed at the full upsized amount following strong investor demand